In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of death by 23% at 24 months compared to enzalutamide in patients with metastatic ...

Patients with metastatic castration-sensitive prostate cancer are recommended to be treated with enzalutamide tablets.

Zydus Lifesciences share price will remain in focus on October 3 after the company received tentative approval from the ...

The pharmaceutical company has received tentative approval from the USFDA to manufacture Enzalutamide tablets in 40 mg and 80 ...

Pharma stock engaged in manufacturing and distributing of pharmaceutical products gained traction on Thursday’s trading ...

On Thursday, 1120 stocks advanced, 2864 declined and 92 remained unchanged, with an advance decline ratio 0.39 on the Bombay Stock Exchange (BSE), indicating negative closing of stocks in broader ...

Adani Enterprises has consolidated its two subsidiaries, Adani Infrastructure and Mundra Solar Technology, into Adani New ...

Here is a list of stocks that are set to be in focus during Thursday's session, as participants return to trade after a day's ...

Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...

In today's trade, shares of Maruti Suzuki, Dabur, Marico, Aurobindo Pharma, Angel One among others will be in focus due to ...

Gift Nifty is indicating at a weak start for Sensex and Nifty. Around 7:20 AM, Gift Nifty, which is an early indicator for ...